{"id":"W4405044303","doi":"10.1182/blood-2024-209438","title":"Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Daiichi Sankyo Europe; Servier; Astellas Pharma; CTI Biopharma; Incyte; MacroGenics; Syndax Pharmaceuticals; BeiGene; Jazz Pharmaceuticals; Alexion Pharmaceuticals; Seagen; Gilead Sciences; GlaxoSmithKline; Amgen","keywords":"Medicine; Regimen; Chemotherapy regimen; Acute lymphocytic leukemia; Chemotherapy; Lymphoblastic Leukemia; Oncology; Pediatrics; Randomized controlled trial; Internal medicine; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004353076,0.0003439759,0.0008974478,0.0002634054,0.00006057307,0.00005907188,0.000323565,0.0002060453,0.00009743974],"category_scores_gemma":[0.0006894554,0.0002162971,0.0001984511,0.001198777,0.0001427132,0.0001613183,0.00007842187,0.0003666155,0.0000652949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009626487,"about_ca_system_score_gemma":0.001654276,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005318134,"about_ca_topic_score_gemma":0.00004507614,"domain_scores_codex":[0.9969731,0.0001808392,0.0007431275,0.0006161657,0.001001747,0.0004850311],"domain_scores_gemma":[0.9975485,0.001327171,0.0001665567,0.0005092289,0.0002557952,0.0001928164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9804386,0.002824485,0.003372831,0.0002425137,0.0008839752,0.0002359366,0.002818056,0.000007881354,0.003409952,0.0000367437,0.004930761,0.0007982964],"study_design_scores_gemma":[0.9863341,0.00219135,0.002079837,0.0005526292,0.00137468,0.00001385568,0.00006281505,0.001165692,0.005868242,0.00005337318,0.00005677187,0.0002466485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941403,0.0002512441,0.0002841016,0.000405252,0.0002114643,0.003911643,0.0003336488,0.00008756847,0.0003747568],"genre_scores_gemma":[0.9967592,0.0002939086,0.000809835,0.0003716795,0.0004996519,0.0005852847,0.0003069439,0.0000828647,0.0002906411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005895537,"threshold_uncertainty_score":0.8820341,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006396132666171618,"score_gpt":0.2523164362831921,"score_spread":0.2459203036170205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}